Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22015839 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL22015934 | 0.85 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL22016025 | 0.79 | SLC7A5 (0.43) | — | |
| SCHEMBL20077209 | 0.77 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL22015691 | 0.75 | THRB (0.37) | SMN1; SMN2ALDH1A1MAPTL3MBTL1 | |
| SCHEMBL23089886 | 0.71 | SMN1; SMN2 (0.37) | SMN1; SMN2 | |
| SCHEMBL22015679 | 0.70 | ZDHHC7 (0.46) | — | |
| Mecysteine SCHEMBL1681698 | 0.68 | — | — | |
| Mecysteine SCHEMBL21034 | 0.68 | — | — | |
| Mecysteine SCHEMBL94255 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008287-B2 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine | EPICENTRX, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200157047-A1 | SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE | EPICENTRX, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008287-B2 | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compounds for use in medicine | AS3MT, SLC10A6, SLCO1B3 | SMN1; SMN2 123/4885ALDH1A1 2681/4885MAPT 1040/4885 |
| US-20200157047-A1 | SULFOXYALKYL ORGANONITRO AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOUNDS FOR USE IN MEDICINE | AS3MT, SLC10A6, SLCO1B3 | SMN1; SMN2 123/4885ALDH1A1 2681/4885MAPT 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.